• Home
  • About
  • Clinical
  • Authors
  • Most read this year
  • GP Opinion
  • Videos & Podcasts
  • Professional
  • Comments policy
  • RACGP
  • poll
Menu

Filter
TGA approves second COVID-19 vaccine for youngest children

TGA approves second COVID-19 vaccine for youngest children

The Pfizer vaccine is now approved for use in children aged six months to five years, with Moderna already available to the age group.


Independent review into COVID vaccine procurement released

Independent review into COVID vaccine procurement released

Eight recommendations have been handed down, with the next two years identified as ‘critical’ to Australia’s recovery.


Vaccine rollout ‘relied on GP goodwill’: Study

Vaccine rollout ‘relied on GP goodwill’: Study

General practices involved in Australia’s COVID-19 vaccination program struggled to make ends meet, researchers say.


Combined flu and COVID-19 tests approved

Combined flu and COVID-19 tests approved

Two separate nasal tests capable of detecting both COVID-19 and influenza have been approved by Australia’s medicines regulator.


Vaccine rollout lessons put on hold

Vaccine rollout lessons put on hold

An Audit Office report contains criticisms of planning and communication but offers few concrete suggestions for improvement.


Study flags knowledge gaps for shingles vaccine

Study flags knowledge gaps for shingles vaccine

Research suggests that misconceptions remain about the shingles vaccine in use for the Government vaccination program for people over 70.


‘Breakthrough moment’: Monkeypox vaccine secured

‘Breakthrough moment’: Monkeypox vaccine secured

The Federal Government has procured 450,000 doses of the MPX vaccine, with the first shipments due to arrive shortly.


ATAGI approves Moderna vaccine for at-risk young children

ATAGI approves Moderna vaccine for at-risk young children

Parents are advised not to contact vaccine providers until bookings open, following decision to approve vaccination for the youngest cohort.


COVID vaccine safety data for children ‘extremely reassuring’

COVID vaccine safety data for children ‘extremely reassuring’

A new study tracking nearly 400,000 children aged 5–15 post-vaccination found adverse events were generally short-term and mild.


TGA green lights Nuvaxovid for 12–17-year-olds

TGA green lights Nuvaxovid for 12–17-year-olds

But while provisional approval has been granted, inclusion in the national program for this age group is yet to be confirmed.


  • Previous
  • ...
  • 4
  • 5
  • 6
  • ...
  • Next
Pages: 6 of 46
RACGP newsGP ArticlesnewsGP

Terms and conditions | Privacy statement | RACGP | recruitGP | AJGP

© 2018 The Royal Australian College of General Practitioners (RACGP) ABN 34 000 223 807